Thiourea derivatives have been shown to posses several biological activities. Therefore a series of N-substituted -N'-(3,5-di/l,3,5-trimethylpyrazole-4-yl)thioureas were synthesized and the antitubercular and anticonvulsant activities were studied. Among the new compounds, N-phenyl-N'-(3,5-dimethylpyrazole-4-yl)thiourea (5) was demonstrated to have remarkable anticonvulsant activity. In this study, S was selected as a model compound and the in vivo metabolic pathway in rats was investigated. The substrate was given intraperitoneally (50 mg/kg) and blood samples were collected at 0, 1,2,4,8, 12,24 and 48 h. The substrate and its potential metabolites were separated using HPLC on reverse phase system. The substrate was detected at all times with small quantity of metabolites.
INTRODUCTION
Thiourea derivatives have attracted considerable attention during the last decades due to their significant biological activities as antitubercular, antiviral, antifungal, anti-HIV, antihypertensive as well as good anticonvulsant properties (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . However among the numerous studies, there are very few concerning the metabolism ofthioureas (12) (13) (14) . We therefore investigated in vivo metabolism of previously synthesized N-substituted-N'-(3,5-dimethylpyrazole-4-yl)thioureas for possible anticonvulsant and antitubercular activities (15).
We usedN-Phenyl-N'-(3,S-dimethylpyrazole-4-yl) thiourea as a substrate and synthesized their potential metabolites. HPLC analysis was used to identify substrate and potential
MATERIALS AND METHODS
N-Phenyl-N' -(3,5 -dimethyl pyrazole-4-yl)thiourea (substrate), N~phenyl-N'-(3,5-dimethylpyrazole-4-yl)urea (M\), 4-amino-3,S-dimethylpyrazole (Mz) were synthesized as reported previously (15, 16) . Only the acetylated metabolite, 4-acetylamino-3,S-dimethylpyrazole (M 3 ) was original. 
Animals
The experiments were reviewed and approved by local Institute's Animal Care and Use Committee. All procedures in this study are in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the National Institutes of Health (USA) and the declaration of Helsinki. Adult male Wistar rats (200-250 g) were used in the study. They were housed in a quiet, temperature (20±2°C) and humidity (60±3 %) controlled room in which a 12/12 h light and dark cycle was maintained (7:00-19:00 ligth), The rats were fed standard lab chow and tap water ad lib during the study. Rats were fasted overnight before administration of substrate. Substrate was dissolved in 5 % gum arabicum and administered 50 mg/kg to rats by intraperitoneally. Blood samples were collected from ophtalmic veins of the rats by sterile capillary tube under ether anesthesia at 0, 1,2,4,8, 12,24 and 48 h after administration. Blood samples were centrifuged at 5000 rpm for 5 min to obtain plasma.
Preparation of standards
Stock standard solutions of M 1 , M z ' M 3 , M 4 , M s' M 6 and substrate were separately prepared in the mobile phase (acetonitril-water) (1 mg/mL), 20 ul, ofthe stock standard solution of each compounds were transferred to tube and diluted to 1mL with mobil phase to give a concentration of 20 ug/ml., Aliquots of 10 ul, of the standard solutions were injected on to the HPLC column. 
Preparation of biological samples
In this study, blood samples were prepared using modified methods of Oruc et al. (17) . The blood samples were centrifuged to separated into plasma and blood cells. 1mL of methanol was added to plasma to precipitate plasma proteins and plasma was centrifuged. The upper phase was removed and passed through a Sep-Pak CIS cartridge. 1 mL of distilled water was added to the lower phase (the precipitated plasma proteins) and this part was heated at 50°-60°C for 3 hours to denaturate proteins. The samples were centrifuged and again passed through a Sep-Pak CIS cartridge. 1 mL of distilled water was added to blood cells and heated. After denaturation, 1 mL methanol was added and from here the procedure was same as above.
In the liquid-solid extraction procedure, samples were loaded onto a Sep-Pak CISwhich were preconditioned by washing with 1 mL of methanol and 1 mL of water and after filtered samples, the cartridge was washed with 1 mL of methanol.
The solvent was removed by lyophilization (freezedrying, model Leybold-Heraeus Lyovac GT 2) and the residue was dissolved in 300 mL of mobile phase and a 10 ul, aliquot was injected onto the HPLC system. 
RESULTS AND DISCUSSION
The in vivo biotransformation of N-phenyl-N'-(3,5-dimethylpyrazole-4-yl)thiourea (substrate) was studied in rats. The substrate and some potential metabolites were synthesized and their chemical structures were elucidated. The potential metabolites of this substrate are shown in Figure 1 .4-Acetylamino-3,5-dimethylpyrazole (M 3 ) was obtained by the reaction of 4-amino-3,5-dimethylpyrazole with acetic anhydride as a new compound. This compound was elucidated using UV, IR and IH-NMR spectroscopic methods. In the IH-NMR spectrum, methyl protons of acetyl group were detected at 2.14 ppm. The pyrazole C s and C 3 methyl protons were observed at 1.83 and 1.90 ppm, respectively. Also M 3 displayedsinglet at 12.10ppm attributed to the pyrazole NH proton.
The substrate was injected (50 mg/kg) into male Wistar albino rats intraperitoneally. After administration of substrate, blood samples were collected at 0, 1,2,4,8, 12, 24 and 48 h. Instead of removing solvent by heating, lyophilization was used.
The spiked plasma was prepared by adding constant concentration of each reference standard into blood. When the spiked plasma were injected onto HPLC column, the retention times of substrate and metabolites were found approximately same with the retention times of reference standards (Figure 2 ). The retention times were observed at 5.867, 12.633,4.167, 11.850,7.400,3.783 and 7.083 min for MI'~, My M 4 , Ms, M 6 and the substrate, respectively.
The substrate was determined at alltimes with the retention times of 7.033±O.085 min. The concentration of substrate increased until 12h then decreasedbut also, it was observed at 48 h (Figure 3 and 4) . According to the Figure 4C , a peak with the same retention time of acetanilid (M5, Rt: 7.367 min) was detected at 48 h. Actually this peak was different from the M, comparing to the UV spectral data results obtained from the Diode Array Dedector (DAD, HP Agilent 1100). And also at 8 h, an unknown peak was observed at the retention time of 6.283 min ( Figure 3D ).
The previous results had established that the substrate and its potential metabolites were bound to the plasma proteins (17, 18) . For this reason, the plasma proteins were denatured by heating (the substrate and the metabolites were resistant for heat) and samples were prepared after denaturation. Both substrate and metabolites were not detected in the denatured plasma proteins at any time.
In this investigation, the results showed that only the undefined metabolites were detected with a low concentration at 8 and 48 h, and also the oxidation metabolite of substrate Mx., MX 2 and MX 3 could not be identified in rat plasma. The substrate, whichwas probably resistant to biotransformation, was metabolized largely unchanged in the plasma. The other important point was that the toxic metabolites like anilin were not detected. Additionally, the absence of 4-amino-3,5-dimethylpyrazolepyrazole (M 2 ) , 4-acetylamino-3,5-dimethylpyrazolepyrazole (M 3 ) or acetanilid (M s) in plasma proved that the substrate was not metabolized to anilin. Furthermore, the substrate was not desulfurated to its urea metabolite. These results suggest that pharmacological activity of thiourea functional group could be unchanged due to not desulfuration to urea group.
